Early research (Phase 1)UnknownNCT05171530What this trial is testingLenvatinib With Taxane Drugs Treatment for Advanced Gastric CancerWho this might be right forHER2-negative Advanced Gastric Cancer Ruijin Hospital 19
Not applicableUnknownNCT06349044What this trial is testingA Randomized, Multicenter Phase II Basket Study of Hypofractionated Radiotherapy/Stereotactic Body Radiotherapy Followed by Immunotherapy-Based Systemic Therapy +/- L. Rhamnosus M9 for the First-Line Treatment of Advanced Digestive System Malignancies.Who this might be right forHer-2 Negative Adenocarcinoma of the Gastro-oesophageal Junction/Gastric AdenocarcinomaHepatocellular CarcinomaBiliary Tract Carcinoma+1 more Zhejiang Cancer Hospital 120
Testing effectiveness (Phase 2)UnknownNCT05170542What this trial is testingThe Neoadjuvant Treatment of Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma.Who this might be right forEfficacy and Safty of Camrelizumab Plus S-1 Maintenance After First-line Induction Chemotherapy for GC Peking Union Medical College Hospital 42
Not applicableLooking for participantsNCT06158919What this trial is testingPD-1 Inhibitors Combined With Fruquintinib and Chemotherapy in First-line Treatment of HER2-negative Advanced G/GEJ CancerWho this might be right forGastric Cancer/Adenocarcinoma of Esophagogastric Junction Fudan University 58
Early research (Phase 1)Active Not RecruitingNCT02264678What this trial is testingAscending Doses of Ceralasertib in Combination With Chemotherapy and/or Novel Anti Cancer AgentsWho this might be right forAdv Solid Malig - H&N SCC, ATM Pro / Def NSCLC, Gastric, Breast and Ovarian Cancer AstraZeneca 358
Not applicableUnknownNCT06034964What this trial is testingTislelizumab Combined With Chemotherapy in First-line Treatment of AGCWho this might be right forTislelizumabChemotherapyFirst-line+1 more Cancer Institute and Hospital, Chinese Academy of Medical Sciences 60
Testing effectiveness (Phase 2)UnknownNCT05198856What this trial is testingThalidomide Combined With Chemotherapy and Monotherapy for Maintenance Treatment for Her2-negative Advanced GCWho this might be right forGastric Cancer Metastatic to Liver Qilu Hospital of Shandong University 106
Early research (Phase 1)Study completedNCT03752398What this trial is testingXmAb®23104 in Subjects With Selected Advanced Solid Tumors (DUET-3)Who this might be right forMelanoma (Excluding Uveal Melanoma)Cervical CarcinomaPancreatic Carcinoma+13 more Xencor, Inc. 198
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06365008What this trial is testingSintilimab Plus FOLFIRI as Second-line Therapy for Patients With HER2-negative Advanced Gastric CancerWho this might be right forUnresectable/Metastatic Gastric Cancer Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University 27
Early research (Phase 1)Looking for participantsNCT06999187What this trial is testingDR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory CarcinomasWho this might be right forTriple Negative Breast CancerHER2-negative Breast CancerNon Small Cell Lung Cancer+9 more Dren Bio 96
Testing effectiveness (Phase 2)Looking for participantsNCT06750185What this trial is testingSafety and Preliminary Effectiveness of BNT317, an Investigational Therapy for Advanced Solid TumorsWho this might be right forAdvanced Solid Tumor BioNTech SE 248
Large-scale testing (Phase 3)Active Not RecruitingNCT05144854What this trial is testingEvaluate the Efficacy and Safety of ONO-4538 in Combination With Ipilimumab and Chemotherapy in Chemotherapy-naïve Participants With HER2-negative Unresectable Advanced or Recurrent Gastric Cancer (Including Esophagogastric Junction Cancer)Who this might be right forGastric Cancer Ono Pharmaceutical Co., Ltd. 626
Large-scale testing (Phase 3)Not Yet RecruitingNCT05914610What this trial is testingEnvollizumab Combined With Fruquintinib and SOX Versus SOX for Conversion Therapy in Advanced Gastric CancerWho this might be right forGastric Cancer Fujian Medical University 100
Testing effectiveness (Phase 2)Ended earlyNCT04168931What this trial is testingTrastuzumab to Patients With Advanced Gastric Cancer With HER2 Positive Expression in CTCWho this might be right forGastric Cancer Stage IV AC Camargo Cancer Center 5
Large-scale testing (Phase 3)Looking for participantsNCT06177041What this trial is testingM108 Plus CAPOX Versus Placebo Plus CAPOX as First-line Treatment for Claudin (CLDN) 18.2-Positive, HER2-Negative, PD-L1 CPS<5, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma.Who this might be right forLocally Advanced Unresectable or Metastatic Gastric CancerLocally Advanced Unresectable or Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma FutureGen Biopharmaceutical (Beijing) Co., Ltd 486
Large-scale testing (Phase 3)Study completedNCT02445209What this trial is testingComparison of Efficacy and Frequency of Adverse Events of 1st Line Palliative Chemotherapy EOX and mDCF Regimens in Advanced HER2-negative Gastric CarcinomaWho this might be right forHER2 Negative Gastric Cancer Jagiellonian University 56
Early research (Phase 1)Ended earlyNCT05252416What this trial is testing(VELA) Study of BLU-222 in Advanced Solid TumorsWho this might be right forAdvanced Solid TumorsHR+ Breast CancerCCNE1 Amplification+6 more Blueprint Medicines Corporation 50
Early research (Phase 1)Looking for participantsNCT06769425What this trial is testingHS-10502 Combination Treatment in Patients With Advanced Solid TumorsWho this might be right forRecurrent Ovarian CancerHER2-negativeAdvanced Breast Cancer+3 more Jiangsu Hansoh Pharmaceutical Co., Ltd. 157
Not applicableUnknownNCT05513144What this trial is testingPotential Clinical Utilities of Circulating Tumor DNA in Advanced HER2 Negative Gastric CancerWho this might be right forGastric CancerCirculating Tumor DNA (ctDNA) chenwu 30
Testing effectiveness (Phase 2)UnknownNCT06284746What this trial is testingTirelizumab Combined With Chemotherapy in the Treatment of HER-2 Negative Locally Advanced Gastric CancerWho this might be right forLocally Advanced Gastric CarcinomaHER2 NegativeEfficacy+1 more Lin Chen 80